You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Using genetic probes and fluorescent scanning, the firm plans to market the $20 test for pathogens that cause urinary tract infections and biological warfare.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Fusion originally developed its synthetic capture probe technology for cancer gene fusion assays but is repurposing it to diagnose infectious diseases.